CompletedPhase 2NCT02758626

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

Studying Epilepsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NYU Langone Health
Principal Investigator
Orrin Devinsky, MD
NYU Langone Health
Intervention
ataluren(drug)
Enrollment
15 enrolled
Eligibility
2-12 years · All sexes
Timeline
20162021

Study locations (1)

Collaborators

PTC Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02758626 on ClinicalTrials.gov

Other trials for Epilepsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Epilepsy syndrome

← Back to all trials